Current Headlines

1. Cambrex Unveils $120 Million Investment To Expand API Manufacturing And Strengthen U.S. Drug Supply Resilience 10/22/2025

   Cambrex, a leading global CDMO, is addressing increased demand for API development and manufacturing and accelerating the company’s leadership role in the fast-growing peptide therapeutics market.

2. Invenra Inc. And Xcellon Biologics Announce Collaboration To Advance Bispecific And Trispecific Antibody-Drug Conjugate (ADC) Development 10/22/2025

   Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs.

3. Charles River And The Francis Crick Institute Combine Expertise In Antibody-Drug Conjugate Development 10/22/2025

   Charles River Laboratories International, Inc. and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.

4. Syngene International Announces Plans To Add Bioconjugation Suite For End-To-End Antibody-Drug Conjugates Development 10/22/2025

   Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru.

5. 7th Inflammasome Therapeutics Summit 10/21/2025

   Now in its 7th year, the Inflammasome Therapeutics Summit is the only industry forum focused exclusively on inflammasome-targeted drug development. Over three action-packed days, we will unpack high-impact case studies from the front lines – covering emerging upstream and downstream targets, mechanisms beyond canonical pathways, and how these insights are unlocking new disease areas from neuroinflammation and atopic dermatitis to obesity and fibrotic conditions.

6. Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation For QRX003 In Netherton Syndrome 10/21/2025

   Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome.

7. Nxera's Partner Cancer Research UK Presents Data From Successfully Completed Phase 1 Clinical Trial Of Cancer Immunotherapy Drug HTL0039732 At ESMO 10/21/2025

   Nxera Pharma (“the Company” or “Nxera”;) announces that its partner, Cancer Research UK, presented data from the successfully completed Phase 1 part of the ongoing Phase 1/2a clinical trial (NCT05944237) of Nxera’s immunotherapy drug HTL0039732 (also known as NXE0039732) at the European Society for Medical Oncology Congress (ESMO) 2025 being held 17-21 October 2025 in Berlin, Germany.

8. Topcon Healthcare Launches IDHea, Inc. To Advance Drug Development And Oculomics 10/21/2025

   Topcon Healthcare, Inc. officially launches IDHea, Inc., the Institute for Digital Health, a new company dedicated to transforming clinical research in eye care and oculomics.

9. Dewpoint Therapeutics Announces An Open IND For First-In-Class Condensate Modulator DPTX3186 For Wnt-Driven Cancers 10/21/2025

   Dewpoint Therapeutics today announced the opening of an Investigational New Drug (IND) application to the U.S.

10. Ventus Therapeutics Enters Into A Collaboration And License Agreement With Genentech To Discover And Develop Small-Molecule Medicines Using Ventus' ReSOLVE Platform 10/21/2025

    Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders, today announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover and optimize novel small-molecule candidates for challenging targets in major disease areas using Ventus’ proprietary drug discovery platform, ReSOLVE.